CL2021003497A1 - Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 - Google Patents
Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1Info
- Publication number
- CL2021003497A1 CL2021003497A1 CL2021003497A CL2021003497A CL2021003497A1 CL 2021003497 A1 CL2021003497 A1 CL 2021003497A1 CL 2021003497 A CL2021003497 A CL 2021003497A CL 2021003497 A CL2021003497 A CL 2021003497A CL 2021003497 A1 CL2021003497 A1 CL 2021003497A1
- Authority
- CL
- Chile
- Prior art keywords
- glp
- glucagon
- agonists
- peptide
- pharmaceutical compositions
- Prior art date
Links
- 108060003199 Glucagon Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 229960004666 glucagon Drugs 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000051325 Glucagon Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000321 Glucagon Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona formulaciones para administración parenteral de péptidos agonistas de GLP-1/glucagón, métodos para producir dichas formulaciones y métodos de tratamiento usando dichas formulaciones
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869263P | 2019-07-01 | 2019-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003497A1 true CL2021003497A1 (es) | 2022-09-30 |
Family
ID=71575348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003497A CL2021003497A1 (es) | 2019-07-01 | 2021-12-27 | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230159606A1 (es) |
| EP (1) | EP3993823A1 (es) |
| JP (1) | JP2022539200A (es) |
| KR (1) | KR20220027204A (es) |
| CN (1) | CN114126639A (es) |
| AR (1) | AR119324A1 (es) |
| AU (1) | AU2020299978A1 (es) |
| BR (1) | BR112021026575A2 (es) |
| CA (1) | CA3144177A1 (es) |
| CL (1) | CL2021003497A1 (es) |
| CO (1) | CO2021017960A2 (es) |
| CR (1) | CR20220046A (es) |
| EA (1) | EA202290107A1 (es) |
| IL (1) | IL289437A (es) |
| MA (1) | MA56448A (es) |
| MX (1) | MX2021015930A (es) |
| PE (1) | PE20220513A1 (es) |
| PH (1) | PH12021553215A1 (es) |
| TW (1) | TW202116814A (es) |
| WO (1) | WO2021001374A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
| TWI674270B (zh) | 2012-12-11 | 2019-10-11 | 英商梅迪繆思有限公司 | 用於治療肥胖之升糖素與glp-1共促效劑 |
| AR104932A1 (es) * | 2015-06-22 | 2017-08-23 | Lilly Co Eli | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
| AU2017229530B2 (en) * | 2016-03-10 | 2020-05-07 | Medimmune Limited | Glucagon and GLP-1 co-agonists for the treatment of obesity |
-
2020
- 2020-06-30 PE PE2021002192A patent/PE20220513A1/es unknown
- 2020-06-30 MA MA056448A patent/MA56448A/fr unknown
- 2020-06-30 EA EA202290107A patent/EA202290107A1/ru unknown
- 2020-06-30 BR BR112021026575A patent/BR112021026575A2/pt unknown
- 2020-06-30 KR KR1020227003224A patent/KR20220027204A/ko active Pending
- 2020-06-30 US US17/618,951 patent/US20230159606A1/en not_active Abandoned
- 2020-06-30 AU AU2020299978A patent/AU2020299978A1/en not_active Abandoned
- 2020-06-30 WO PCT/EP2020/068411 patent/WO2021001374A1/en not_active Application Discontinuation
- 2020-06-30 PH PH1/2021/553215A patent/PH12021553215A1/en unknown
- 2020-06-30 CN CN202080047698.6A patent/CN114126639A/zh active Pending
- 2020-06-30 EP EP20739285.3A patent/EP3993823A1/en not_active Withdrawn
- 2020-06-30 CA CA3144177A patent/CA3144177A1/en active Pending
- 2020-06-30 MX MX2021015930A patent/MX2021015930A/es unknown
- 2020-06-30 JP JP2021577897A patent/JP2022539200A/ja active Pending
- 2020-06-30 CR CR20220046A patent/CR20220046A/es unknown
- 2020-07-01 AR ARP200101860A patent/AR119324A1/es not_active Application Discontinuation
- 2020-07-01 TW TW109122310A patent/TW202116814A/zh unknown
-
2021
- 2021-12-27 CL CL2021003497A patent/CL2021003497A1/es unknown
- 2021-12-27 IL IL289437A patent/IL289437A/en unknown
- 2021-12-28 CO CONC2021/0017960A patent/CO2021017960A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220027204A (ko) | 2022-03-07 |
| AR119324A1 (es) | 2021-12-09 |
| CA3144177A1 (en) | 2021-01-07 |
| MX2021015930A (es) | 2022-02-03 |
| PE20220513A1 (es) | 2022-04-07 |
| CR20220046A (es) | 2022-03-24 |
| AU2020299978A1 (en) | 2022-02-24 |
| EA202290107A1 (ru) | 2022-03-29 |
| WO2021001374A1 (en) | 2021-01-07 |
| US20230159606A1 (en) | 2023-05-25 |
| CN114126639A (zh) | 2022-03-01 |
| MA56448A (fr) | 2022-05-11 |
| TW202116814A (zh) | 2021-05-01 |
| JP2022539200A (ja) | 2022-09-07 |
| IL289437A (en) | 2022-02-01 |
| EP3993823A1 (en) | 2022-05-11 |
| PH12021553215A1 (en) | 2022-11-07 |
| BR112021026575A2 (pt) | 2022-04-26 |
| CO2021017960A2 (es) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| JOP20190229A1 (ar) | مركبات تثبط بروتين mcl-1 | |
| CY1121675T1 (el) | Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων | |
| CL2017002022A1 (es) | Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| MA40539A (fr) | Procédés de formulation de compositions de conjugués anticorps-médicaments | |
| MX392683B (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| MX388786B (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| BR112016026811A2 (pt) | formulação de anticorpo | |
| PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
| ZA202107825B (en) | Pharmaceutical parenteral composition of dual glp1/2 agonist | |
| EA201790254A1 (ru) | Новые модуляторы рецептора glp-1 | |
| CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
| MX2018010032A (es) | Formulaciones de antagonista de il-6 y sus usos. | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| BR112017025000A2 (pt) | tratamento de hipoglicemia pós-bariátrica com exendina (9-39) | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
| MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
| CL2021001479A1 (es) | Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391) | |
| PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
| CL2021003497A1 (es) | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. | |
| AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) |